Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation
| Autor: | Philippe Beutels, V. Hutse, P. Van Damme, Karel Hoppenbrouwers, Heidi Theeten |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Hepatitis B virus HBsAg Pediatrics medicine.medical_specialty Adolescent Epidemiology medicine.disease_cause Mass Vaccination Serology Young Adult Belgium Seroepidemiologic Studies medicine Humans Hepatitis B Vaccines Hepatitis B Antibodies Young adult Child Immunization Schedule business.industry Infant virus diseases Hepatitis B medicine.disease Original Papers digestive system diseases Vaccination Infectious Diseases Child Preschool Immunology Female Human medicine Serostatus business |
| Zdroj: | Epidemiology and infection Epidemiol Infect |
| ISSN: | 1469-4409 0950-2688 |
| DOI: | 10.1017/s0950268813001064 |
| Popis: | SUMMARYHepatitis B virus (HBV) can be eliminated by effective universal vaccination. In Belgium, a free-of-charge HBV vaccination programme in infants with catch-up in adolescents was introduced in 1999. To evaluate the effects in 11 mIU/ml, according to the assay) and markers of infection (anti-HBc, HBsAg) were assessed in 2443 residual sera collected 7–8 years after implementation of the programme. The maximal prevalence of a solely anti-HBs seroprotective (‘vaccinated’) serostatus was 82·9% at age 1 year and 60·5% at age 13 years. A clear increase was found in age cohorts targeted by the campaign after a similar serosurvey conducted 4 years earlier. The prevalence of HBV infection remained unchanged at a low level (1·8% in 2006) similar to pre-vaccination data (1993–1994). We conclude that universal HBV vaccination has achieved overall high levels of vaccine-induced immunity, despite regional variations, which may give rise to pockets of susceptible young adults in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|